Coronavirus Update: Pfizer/BioNTech, Moderna Submit Omicron EUAs For Fall Season
Under FDA guidance, the companies submitted clinical data for BA.1-targeting bivalent vaccines together with BA.4/BA.5 preclinical data. Novavax got a nod for its COVID-19 vaccine in adolescents, but its own Omicron development efforts remain behind the two mRNA heavyweights.
You may also be interested in...
Moderna Lauds Joint Work With Health Authorities On Spikevax Safety Monitoring
A senior executive at Moderna recounts how the company used a variety of data sources to identify potential safety signals for its Spikevax COVID-19 vaccine during a state of “hyper-pharmacovigilance.”
Valneva Confirms Step Back From COVID-19 Vaccine Development
The French firm has suspended the manufacturing of its COVID-19 vaccine, instead emphasizing its hopes in advanced Lyme disease and Chikungunya.
Pfizer Strengthens Foundation For A Long-Term COVID Commercial Business
Preparing for the eventual transition to an open commercial market for COVID-19 vaccines and treatments, Pfizer restructured its commercial team to incorporate the franchises.